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Background
The aim of this study was to validate the Mantle Cell Lymphoma International Prognostic
Index in a population-based cohort and to study the relevance of its revisions.
Design and Methods
We analyzed data from 178 unselected patients with stage III or IV mantle cell lymphoma, reg-
istered between 1994 and 2006 in the Eindhoven Cancer Registry. Follow-up was completed
up to January 1st, 2008. Multiple imputations for missing covariates were used. Validity was
assessed by comparing observed survival in our cohort with predicted survival according to the
original Mantle cell lymphoma International Prognostic Index. A revised model was construct-
ed with Cox regression analysis. Discrimination was assessed by a concordance statistic (‘c’). 
Results
The original Mantle cell lymphoma International Prognostic Index could stratify our cohort
into three distinct risk groups based on Eastern Cooperative Group performance status, white
blood cell count, lactate dehydrogenase level, and age, with the discrimination being nearly as
good as in the original cohort (c 0.65 versus 0.63). A modified model including performance sta-
tus in five categories (0/1/2/3/4) instead of two (0-1/2-4), the presence of B-symptoms (yes/no)
and sex (male/female) in addition to the original variables resulted in a better prognostic index
(c 0.75). 
Conclusions
The Mantle cell lymphoma International Prognostic Index is a valid tool for risk stratification,
comparison of prognosis, and treatment decisions in an unselected Dutch population-based
setting. Although the index can be significantly improved, external validation on an independ-
ent data set is warranted before broad application of the modified instrument could be recom-
mended.
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Introduction
Mantle cell lymphoma (MCL) is a relatively rare lym-
phoma entity accounting for approximately 3% to 6% of
all cases of non-Hodgkin’s lymphoma. It has a poor prog-
nosis with a reported median overall survival of only 30 to
43 months. Treatment results have been unsatisfactory,
although a substantial variation in outcome has been noted
among individual cases with some patients achieving long-
lasting remissions.1 A validated prognostic index would
greatly help in developing new treatment strategies based
on risk and prognosis, and for evaluating and choosing
between different available treatment options.
Recently, a new clinical prognostic index was proposed
for MCL: the Mantle Cell Lymphoma International
Prognostic Index (MIPI).1 This index is based on data
derived from three large randomized clinical trials and pro-
poses three risk groups according to the probability of sur-
vival. The score was defined on 455 patients. Several can-
didate prognostic factors were included, but same of these
were excluded in multiple regression, because of a high
number of missing values. 
In the original MIPI, a four-variable model included the
risk factors Eastern Cooperative Group (ECOG) perform-
ance status, white blood cell (WBC) count, lactate dehydro-
genase (LDH) level, and age.1 However, the MIPI has not
been validated yet. Validation is particularly important in a
population-based setting in order to prove the usefulness of
the index in a general health care environment including
more patients with advanced age and/or severe co-morbid-
ity. Restrictive eligibility criteria, such as advanced age, seri-
ous comorbidity, poor performance status and impairment
of organ function, might have biased the results of the trial-
based series.2 We previously found that comorbid condi-
tions were present in 48% of unselected patients with
aggressive non-Hodgkin’s lymphoma under the age of 60,
and in as many as 79% of those older than 60.3
Comorbidity, if serious enough, is an independent prognos-
tic factor.4-6 
We recently showed that the performance of the
Follicular Lymphoma International Prognostic Index (FLIPI)
could be significantly improved by a more refined coding
of age and by including the presence of cardiovascular dis-
ease.7 We, therefore, considered that the performance of
the MIPI might also be improved by adding others risk fac-
tors, including comorbidity. 
The aim of this study was to validate the original MIPI in
a population-based cohort and to study possibilities for
improving the index.
Design and Methods
Study population and data collection
The Eindhoven Cancer Registry records data on all patients
newly diagnosed with cancer in the southern part of the
Netherlands, an area with 2.4 million inhabitants, ten general hos-
pitals and two large radiotherapy institutes.8 Treatment decisions
are generally made in multi-disciplinary meetings, within the
framework of the comprehensive cancer center. Trained registra-
tion clerks actively collect data on diagnosis, topography, histol-
ogy, stage and information about initial treatment (delivered with-
in 6 months after diagnosis) from hospital medical records. The
medical record is generally regarded as the most complete source
of information on a patient’s past and current health status.9
Since 1993 the Eindhoven Cancer Registry also registers the
presence of serious comorbidity with prognostic impact at the
time of cancer diagnosis, using a slightly modified version of the
widely used Charlson comorbidity index.4,10 Comorbidity was
defined as any other disease that was present at the time of can-
cer diagnosis. Comorbidities were registered as dichotomous vari-
ables (yes/no), according to the medical history of the patient, the
use of relevant drugs and diagnostic work-up. Cardiovascular dis-
ease and chronic obstructive pulmonary disease are diseases with
significant influence on survival.3,11 These were analyzed separate-
ly for their impact on prognosis. Cardiovascular disease included
myocardial infarction, heart failure, angina pectoris, coronary
artery bypass graft, peripheral arterial disease and cerebrovascular
diseases.
Data from our regional cancer registry were handled according
to the specifications of the officially recognized code of conduct
on the use of data in health research.
All patients with stage III and IV MCL newly diagnosed
between 1994 and 2006 were included (N=181). Selection was
based on the World Health Organization (WHO) classification,
documented from the medical records and registered in the cancer
registry as ICD-O-3 morphology code 9673 and ICD-O-2 mor-
phology code 9672, with the exclusion of tumors with localization
in the stomach, bowel, lung, salivary glands, eye and skin. Patients
with lymphoma diagnosed at autopsy were not selected.
Additional data [Performance status according to WHO criteria,
LDH level, hemoglobin level, albumin level, beta-2-microglobulin,
Ki-67, chemotherapeutic regimen, platelets and WBC counts (lym-
phocytes, granulocytes and monocytes)] were collected from a
new study of the medical records.
A prognostic index was calculated according to the original
MIPI:1 MIPIoriginal/refitted score = 0.03535*age (years) + 0.6978 (if ECOG
>1) + 1.367*log10 LDH (ULN) + 0.9393*log10 WBC (106). 
This score classifies patients with a total score below 5.7 as low
risk, patients with a score of 5.7 to 6.2 as intermediate risk and
patients with a score equal to or higher than 6.2 as high risk.1
Follow-up was completed up to January 1st, 2008, with vital sta-
tus obtained from the municipal personal records. Survival time
was defined as the time from diagnosis until death or the end of
the study.
Statistical analysis
Missing values may occur selectively across patients. Exclusion
of patients with missing values might, therefore, bias the results.
We, therefore, imputed missing covariates using correlations
between variables. We used a multiple imputation procedure in
which each missing value was imputed five times. Imputed values
were drawn from the predictive distribution in an imputation
model that included all risk factors (age, LDH, total leukocyte and
lymphocyte, granulocyte, and platelet counts, performance status,
number of comorbidities, cardiovascular disease, chronic obstruc-
tive pulmonary disease, sex, spleen involvement, B-symptoms,
stage, albumin and hemoglobin) and the survival outcome.
Imputation of missing predictor values using the outcome is pre-
ferred over imputation without outcome and is not self-fulfilling
prophecy.12 The variation among the five imputations reflects the
uncertainty with which the missing values can be predicted.
Multiple imputations resulted in five completed datasets, which
were analyzed with standard statistical methods. The results were
combined to produce overall estimates and standard errors that
reflected missing data uncertainty.13 All analyses were performed
for both complete cases as well as for single and multiple imputa-
tions. All results are reported with multiple imputed data, except
for the Kaplan-Meier analyses, which were based on a single
imputed data set. We checked the results of the randomly chosen
S.A.M. van de Schans et al.
1504 haematologica | 2010; 95(9)
single imputations, and these were comparable with those of the
multiple imputation.
Validation of the MIPI started with a comparison of the hazard
ratios of the risk factors (refitted MIPI). We checked whether the
coefficients in the Cox regression equation needed to be updated,
based on likelihood ratio statistics,14 and whether other cut-off
points should be used for the categorical variables (revised MIPI).
Next, we considered the extension of the model to include chron-
ic obstructive pulmonary disease (yes/no), cardiovascular disease
(yes/no), the number of comorbidities (yes/no or no/one/more
than one), and a combination of these variables. We calculated the
explained variation by the covariates as R2 = 1 – exp (-LR/n), where
LR is the likelihood ratio. Furthermore we evaluated whether sex,
the presence of B-symptoms, stage, chemotherapeutic regimen,
transplantation, hemoglobin level, beta-2-microglobulin level,
albumin level and lymphocyte, granulocyte, monocyte and
platelet counts, and a combination of these variables could further
improve the MIPI (modified MIPI). We used a stepwise approach,
to include the variable which improved the model most. Finally
we tested the value of Ki-67 level, to validate the biological index
of MIPI (MIPIb). 
We used the c-statistic to study discrimination, which reflected
the ability of the modified MIPI to assign higher predicted risks to
subjects who died during the follow-up than to subjects who sur-
vived during the follow-up period. We used a bootstrap re-sam-
pling procedure to correct for statistical optimism in the c-statistic
for the refitted and modified models. Modeling was repeated in
200 bootstrap samples, with model testing in the original sample.15
Statistical analyses were performed using SAS software (version
9.1, SAS Institute Inc., Cary, North Carolina, USA, 1999), and R
software (v 2.5.1, R Foundation for Statistical Computing, Vienna,
Austria), with multiple imputation using the aregImpute function.
Results
Of the 181 patients with stage III or IV MCL, three were
excluded, because sufficient information could not be
obtained for them. Our population-based study included
more patients with advanced age and more patients with
a lower performance status, as compared to the original
MIPI study (Table 1). As seen in the original study, the per-
centages of missing values were high for lymphocyte,
granulocyte, and monocyte counts, and albumin and
serum b2-microglobulin levels. Furthermore it was difficult
to gather data on functional status from the medical
records in a quarter of the patients. Ki-67 was tested only
sporadically and for 78% of the patients information
about this test was missing. For those tumors for which
Ki-67 testing was done, the test result in the medical
record varied from an exact percentage to a description of
the results (for example positive or high). We tried to
divide these results into three categories: low or less than
10%, positive or between 10% and 29%, and high or 30%
or above.
In our study population 126 patients died, with the 1-
and 5-year survival rates being 80% and 34%, respective-
ly, resulting in a lower median overall survival than in the
original study (26 versus 57 months), with a median fol-
low-up of the surviving patients of 47 versus 32 months,
respectively. 
For 60 patients the MIPI score could not be calculated
because of missing values. The 118 MCL patients with
complete data were categorized as low (31%), intermedi-
ate (19%) and high risk (51%), according to the MIPI
score. With multiple imputations these proportions
changed to 28%, 23%, and 49%, respectively. The 1- and
5-year overall survival rates in the low-risk group were
88% and 54%, those in the intermediate-risk group were
83% and 41%, while the high-risk group had the worst
overall survival rates: 68% and 20%, respectively. The
MIPI score discriminated our cohort nearly as well as the
original cohort (c 0.65 versus 0.63). 
While the discrimination of the whole model was com-
parable, the hazard ratio of performance status was some-
what higher, and the hazard ratios of LDH level and WBC
count were a little lower than in the original study (Table
2). To correct for the underestimation of performance sta-
tus in the original MIPI we considered using the ECOG
score in five categories in the revised model.
Furthermore, we investigated whether extending the
model could improve the prognostic index. The R2 of the
refitted MIPI model was 23%, with a likelihood ratio of
47. A modified model which also included the presence of
B symptoms and sex resulted in a substantially and signif-
icantly (P<0.001) better R2 (49%) and likelihood ratio
(121). Hemoglobin level, albumin level, number of comor-
bidities and the presence of cardiovascular disease were
significant prognostic factors in univariate analyses (data
not shown). However, at multivariate analysis the MIPI
model could not be further improved by extension to
include chronic obstructive pulmonary diseases, cardio-
vascular disease, number of comorbidities, stage, treat-
ment, transplantation, hemoglobin level, albumin level,
beta-2-microglobulin level, or lymphocyte, granulocyte,
monocyte and platelet counts (data not shown). 
The modified model can be calculated by: MIPImodified
score = 0.0453*age (years) + 0.5706*ECOG (subgroup) +
0.3854*log10 LDH (ULN) + 0.2035*log10 WBC (106) +
0.7994 (if B symptoms present) + 0.7820 (if male patient).
Three subgroups were defined with the cut-off points 4.65
and 5.90, leading to some loss in prognostic performance
(R2 43% and likelihood ratio 100). Potential cut-points
were assessed as in the original study in order to find the
best discrimination between groups.1 The low-risk group
contained 64 (36%) patients, the intermediate-risk group
75 (42%) and the high-risk group 39 (22%) patients. The
median survival times were 90, 29, and 6 months in the
low, intermediate and high risk groups, as defined by the
modified MIPI, compared to more than 90, 51, and 29
months, respectively, for groups defined by the original
MIPI. This resulted in 1- and 5-year overall survival rates
of 95% and 66% for the low-risk group, 81% and 24% for
the intermediate-risk group and 38% and 0% for the high-
risk group. The modified model provided a better discrim-
ination of groups with different survival rates than that
provided by the original MIPI (Figure 1). 
As regards the biological index (MIPIb), we tried to col-
lect data on the proliferation marker Ki-67, but this marker
was not tested or poorly recorded in the medical records.
For those cases with an available test on Ki-67 the positivi-
ty did not contribute to the MIPI when divided into four
categories. No improvement in the MIPI was noted even
with multiple imputations of the missing Ki-67 values. 
Discussion
Prognostic models should be valid for daily clinical prac-
tice, allowing risk stratification and comparison of prog-
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nosis, thus providing a rationale for treatment decisions.
Validation of a prognostic index in population-based set-
tings is important because it shows whether the index is
functional in daily practice. In our population-based set-
ting the MIPI was valid, but could be significantly
improved by a more refined coding of performance status
and by including the presence of B symptoms and sex as
risk factors.
The most likely reason for the higher proportion of
patients with advanced age in our population-based
cohort is that the original study was based on data from
clinical trials, with restrictive selection criteria. For
S.A.M. van de Schans et al.
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Table 1. Patients’ baseline  characteristics.
Parameter Original study1 Current study
Total number of patients 455 178
Median age, years (range) 60 (34-86) 67 (40-89)
Males (%) 344 (76) 124 (70)
Missing (%) 0 (0) 0 (0)
ECOG=0 (%) 147 (33) 70 (52)
ECOG=1 (%) 263 (58) 34 (25)
ECOG=2 (%) 20 (15)
ECOG=3 (%) 42 (9) 5 (4) 30 (22)*
ECOG=4 (%) 5 (4)
Missing (%) 3 (1) 44 (25)
Stage=4 (%) 384 (84) 141 (79)
Missing (%) 0 (0) 0 (0)
B-symptoms present (%) 196 (43) 62 (38)
Missing (%) 4(1) 16 (9)
Median WBC count, 109/L (range) 7.9 (1.0-764) 9.2 (1.4-360)
Missing (%) 4 (1) 2 (1)
Median lymphocyte count, 109/L (range) 2.1 (0.35-625) 13.7 (0.13-116)
Missing (%) 33 (7) 19 (11)
Median granulocyte count, 109/L (range) 4.2 (0.19-26.4) 4.0 (0.0-88)
Missing (%) 42 (9) 84 (47)
Median monocyte count, 109/L (range) 0.5 (0.014-10.9) 1.1 (0.0-40)
Missing (%) 47 (10) 28 (16)
Median platelet count, 109/L (range) 188 (3-1346) 178 (10-626)
Missing (%) 3 (1) 3 (2)
Median LDH, /ULN (range) 0.86 (0.15-5.3) 1.03 (0.09-25.5)
Missing (%) 12 (3) 18 (10)
Median Hb (males), g/L (range) 133 (55-175) 126 (59-168)
Median Hb (females), g/L (range) 124 (30-149) 120 (51-152)
Missing (%) 2 (0.4) 1 (1)
Median albumin, /ULN (range) 0.8 (0.36-1.26) 0.81 (0.34-1.08) 
Missing (%) 187 (41) 48 (27)
Median b2-microglobulin, /ULN (range) 1.1 (0.06-8) 2.3 (0.6-4.6)
Missing (%) 170 (37) 119 (67)
Ki-67 Median: 14.5% range: (1.2-91.0) Low: 9 (23%)
Positive: 13 (33%)
High: 18 (45%)
Missing (%) 219 (48) 138 (78%)
No comorbidity - 73
1 comorbid condition - 44
>1 comorbid conditions - 51
Missing (%) - 10 (6)
Chronic obstructive pulmonary disease (%) - 17
Cardiovascular disease (%) - 43
*Treatment CHOP: 255 (56%) CHOP (like): 76 (43%)
RCHOP: 141 (31%) R-CHOP: 27 (15%)
MCP: 50 (11%) Induction treatment for ASCT: 7 (4%)
Other:9 (2%) Palliative CT: 34 (19%)
None: 31 (18%)
Missing (%) 0 (0) 3 (2)
ECOG: Performance status, WBC: white blood cell, LDH: serum lactate dehydrogenase level; Hb: hemoglobin level, *Treatment: CHOP (like) = CHOP, CATPBV, CAVMP/BV. Induction
treatment for autologous stem cell transplantation (ASCT) : CHOP+DHAP/VIM, RCHOP+ high dose Ara-C, high dose Ara-C. Palliative chemotherapy (CT) = CVP,  Chlorambucil, VMP,
CECP.
}
instance the European MCL trial16 had an age limit of up
to 65 years. Furthermore all three trials16-18 that formed the
basis for the original study excluded patients with serious
concomitant diseases, poor performance status, or signifi-
cant impairment of organ function.1 We found the prog-
nostic value of age to be independent of the presence of
co-morbidity and performance status and might, there-
fore, reflect unknown co-morbid or pathophysiological
conditions more frequently encountered in elderly
patients with subsequent less tolerance of treatment. 
In several studies comorbidity was found to be an inde-
pendent prognostic factor for survival in patients with
non-Hodgkin’s lymphoma.3,6 Although the presence of
comorbidity in general, and cardiovascular disease in par-
ticular, were significant prognostic factors in univariate
analyses, these factors did not improve the prognostic per-
formance of the MIPI model. This is probably explained
by the fact that performance status was included in the
model, and this factor partly reflects the presence of
comorbidity.19 The higher proportion of patients with a
poorer performance status in our study could also be the
reason for the relatively low impact of performance status
in the original model containing only very few patients
with a poor performance status.
It remains to be debated whether the poor prognosis
associated with advanced age and poorer performance sta-
tus should be a reason for a different, more aggressive
treatment approach, because previous studies have shown
that such patients experience more side effects of treat-
ment.20 This aspect should preferably be investigated
prospectively. Furthermore, studying cause-specific sur-
vival may also help to unravel this issue, since part of the
worse prognosis might also be due to mortality from the
comorbidity itself.
The above mentioned factors could also be the explana-
tion for the lower median survival in our study compared
to that in the original study.1 Of note, the survival rates in
other population-based studies were similar to that in our
study.21,22
The incidence of MCL is known to be higher in
males.1,21,23 Although sex was not found to have a prognos-
tic effect in either the original study or in other stud-
ies,1,3,21,24 it did improve the MIPI significantly in our study.
In diffuse large B-cell lymphoma the prognostic effect of
sex was found after the introduction of rituximab treat-
ment.25 In our study only 4% of the patients were treated
with rituximab, so we do not think that this treatment
could explain the emergent prognostic effect of sex. Since
we cannot provide a good explanation for this effect, it is
important to validate the modified MIPI, with sex as a
covariate, in other populations.
Another interesting observation in our study is that the
presence of B-symptoms had an important prognostic
effect and could improve the MIPI. This effect had also
been reported in univariate analyses in some earlier stud-
ies,1,26 but disappeared in multivariable analyses, in con-
trast to other studies which showed that it was an impor-
tant independent risk factor also in multivariable analy-
ses.21,27
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Table 2. Hazard ratios and 95% confidence intervals in the original, refitted, and modified MIPI models.
HR (95%CI) MIPI original HR (95%CI) MIPI refitted HR (95%CI) MIPI modified
Age (1 year older) 1.04 (1.02-1.06) 1.04 (1.03-1.05) 1.05 (1.04-1.06)
ECOG (2-4 vs. 0-1) 2.01 (1.19-3.39) 2.75 (2.21-3.42) -
LDH (10-fold) 3.92 (1.48-10.37) 1.48 (1.08-2.03) 1.47 (1.08-2.00)
WBC count (10-fold) 2.56 (1.66-3.95) 1.97 (1.52-2.54) 1.23 (0.96-1.57)
ECOG (4 vs. 3 vs. 2 vs. 1 vs. 0) - - 1.77 (1.61-1.95)
B-symptoms (yes vs. no) - - 2.22 (1.80-2.74)
Sex (male vs. female) - - 2.19 (1.77-2.70)
*C statistic 0.65 0.63 0.75
The original MIPI is the model and the data from the article of Hoster et al.1 The refitted model is the original MIPI model and our population-based data. The modified model is
the model we created after validation, revision and extension. HR: hazard ratio, 95%CI: 95% confidence interval, ECOG: performance status, LDH: serum lactate dehydrogenase
level, WBC: white blood cell. *The C statistic is corrected for optimism with bootstrapping, after division into three subgroups.
Figure 1. Kaplan-Meier curve of the refitted and modified MIPI. 1 =
low-risk group, 2 = intermediate-risk group, 3 = high-risk group.
Numbers of patients, per subgroup and time period, are presented
at the bottom of the figure. Figure based on a single imputation of
missing covariates.
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The prognostic effect of the biological marker Ki-67
could not be tested reliably in our study because of a very
high percentage of missing values and no specific coding
in the medical records. The percentage of missing values
in the original study (48%) was also high. Since recent
studies have shown that Ki-67 is an important prognostic
factor in patients with MCL,24,26,28-30 it is important that the
prognostic significance of Ki-67 in the MIPI model should
be investigated. 
The current analyses did not include patients with limit-
ed stage I or II MCL, because the MIPI was not designed for
these patients. Hoster et al.1 stated that the prognostic rele-
vance of stage was not consistently seen in the literature.
Moreover, the proportion of patients with stage I or II dis-
ease is rather low in MCL and patients with such disease
require a different therapeutic approach. Thus Hoster et al.
limited their investigation to patients with advanced stage
MCL managed with standardized treatment options
(CHOP, 56%; R-CHOP, 31%; and MCP, 11%).16-18 The orig-
inal data were also limited to patients who should have tol-
erated moderately intensive chemotherapy. In our study
the proportion of unselected patients receiving moderately
intensive treatment was obviously lower than in trial-based
studies, such as those on which the original publication was
based. More patients were treated with relatively mild reg-
imens (43% with CHOP or CHOP-like regimens, 15%
with R-CHOP, 4% with induction treatment for autologous
stem cell transplantation, 19% with palliative chemothera-
py and 18% with no chemotherapy). Treatment decisions
are probably correlated with prognostic factors in our retro-
spective study. When we included treatment in our multi-
variate analyses, this variable gave no additional prognostic
value over the other factors of the MIPI and we can, there-
fore, conclude that the other prognostic factors are more
important for this population of patients. 
Several candidate prognostic factors were included in
the original study,1 but some of these were excluded from
the multiple regression analysis because of a high number
of missing values. It is now widely recognized that com-
plete case analyses with missing values in the data set can
lead to bias of the results and are statistically inefficient.13
Nowadays, methods for handling missing data are becom-
ing more standard and software is more readily available.
Multiple imputation is considered a sound statistical
methodology for handling complex missing data prob-
lems,13,31 thereby contributing to statistically more reliable
retrospective analyses, including ours.
In conclusion, the MIPI is a valid instrument for aiding
risk stratification, comparison of prognosis, and treatment
decisions in the setting of an unselected Dutch population
of patients with MCL. Although the MIPI can be signifi-
cantly improved, external validation on an independent
data set is warranted before broad application of the mod-
ified index can be recommended.
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